Disarming myeloid resistance in CAR T therapy

John M. Warrington; Nathan Singh

doi:10.1016/j.ccell.2025.06.003

Disarming myeloid resistance in CAR T therapy

John M. Warrington
, Nathan Singh

Research output: Contribution to journal › Comment/debate

Abstract

Uncovering mechanisms of resistance to chimeric antigen receptor (CAR) T cell therapy for B cell lymphoma is of paramount importance. In this issue of Cancer Cell, Stahl et al. identify a CSF1R⁺ myelo-monocytic population that disrupts CAR T cell function and show that inhibition of CSF1R enhances efficacy of CD19-targeted CAR T cells.

Original language	English
Pages (from-to)	1392-1393
Number of pages	2
Journal	Cancer Cell
Volume	43
Issue number	8
DOIs	https://doi.org/10.1016/j.ccell.2025.06.003
State	Published - Aug 11 2025

Access to Document

10.1016/j.ccell.2025.06.003

Cite this

@article{5fb12ed3bd394516893bc66d712eeb15,

title = "Disarming myeloid resistance in CAR T therapy",

abstract = "Uncovering mechanisms of resistance to chimeric antigen receptor (CAR) T cell therapy for B cell lymphoma is of paramount importance. In this issue of Cancer Cell, Stahl et al. identify a CSF1R+ myelo-monocytic population that disrupts CAR T cell function and show that inhibition of CSF1R enhances efficacy of CD19-targeted CAR T cells.",

author = "Warrington, \{John M.\} and Nathan Singh",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc.",

year = "2025",

month = aug,

day = "11",

doi = "10.1016/j.ccell.2025.06.003",

language = "English",

volume = "43",

pages = "1392--1393",

journal = "Cancer Cell",

issn = "1535-6108",

number = "8",

}

TY - JOUR

T1 - Disarming myeloid resistance in CAR T therapy

AU - Warrington, John M.

AU - Singh, Nathan

PY - 2025/8/11

Y1 - 2025/8/11

N2 - Uncovering mechanisms of resistance to chimeric antigen receptor (CAR) T cell therapy for B cell lymphoma is of paramount importance. In this issue of Cancer Cell, Stahl et al. identify a CSF1R+ myelo-monocytic population that disrupts CAR T cell function and show that inhibition of CSF1R enhances efficacy of CD19-targeted CAR T cells.

AB - Uncovering mechanisms of resistance to chimeric antigen receptor (CAR) T cell therapy for B cell lymphoma is of paramount importance. In this issue of Cancer Cell, Stahl et al. identify a CSF1R+ myelo-monocytic population that disrupts CAR T cell function and show that inhibition of CSF1R enhances efficacy of CD19-targeted CAR T cells.

UR - https://www.scopus.com/pages/publications/105009283625

U2 - 10.1016/j.ccell.2025.06.003

DO - 10.1016/j.ccell.2025.06.003

M3 - Comment/debate

C2 - 40578358

AN - SCOPUS:105009283625

SN - 1535-6108

VL - 43

SP - 1392

EP - 1393

JO - Cancer Cell

JF - Cancer Cell

IS - 8

ER -

Disarming myeloid resistance in CAR T therapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this